Neuralstem, Inc. (NYSE Alternext US: CUR) announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The Company is planning to treat ALS patients through spinal injections of its stem cells via its patented Human Neural Stem Cell technology.
-
Congenital Muscular Dystrophy
A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...-
Upcoming Fundraisers
- Minnesota 1/2 Marathon
4 August 2011
St Paul, MN - Ruby's Diner Hosts Cure CMD Fundraiser
19 February 2012
Rolling Hills Estates, CA 90274 - Long Branch 1/2 Marathon
6 May 2012
Long Branch, NJ - Charlie's Take Me Out To The Ballgame!!
8 July 2012
New York - Disneyland 1/2 Marathon
2 September 2012
Anaheim, CA
- Minnesota 1/2 Marathon
-
CureCMD on Twitter